{"entity":{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","aka":["Jules Bordet Institute","Bordet","Hôpital Universitaire de Bruxelles"],"tldr":"Belgium's only hospital devoted entirely to cancer, birthplace of the Breast International Group and a world centre for breast cancer trials.","summary":"The Institut Jules Bordet opened in 1939, named after the Nobel laureate immunologist Jules Bordet, and moved to a new building beside Erasme Hospital in Anderlecht in 2021 as part of the Hôpital Universitaire de Bruxelles. It is OECI-accredited as a comprehensive cancer centre. Martine Piccart co-founded the Breast International Group here and led the HERA trial of adjuvant trastuzumab; Christos Sotiriou's laboratory developed gene expression signatures for breast cancer and Michail Ignatiadis leads circulating tumour DNA studies, while Ahmad Awada's early-phase unit tests new agents. Bordet is also strong in haematology, nuclear medicine and surgical oncology, and Brussels hosts both BIG and EORTC headquarters.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Institut_Jules_Bordet","links":[{"label":"Homepage","url":"https://www.bordet.be"},{"label":"Breast International Group","url":"https://www.bigagainstbreastcancer.org"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","tnbc","dlbcl"],"sections":["targeted-therapy"],"technologies":["liquid-biopsy","monoclonal-antibody","rna-seq","endocrine-therapy"],"targets":[],"drugs":["trastuzumab","pembrolizumab"],"companies":["big","curie-nki-eortc"],"institutions":["oeci"],"pathways":[],"terms":["ctdna"],"trials":[],"people":["martine-piccart","evandro-de-azambuja","renaud-witmeur","sacha-gougnard"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brussels","country":"BE","lat":50.813,"lng":4.265,"institutionType":"cancer-center","website":"https://www.bordet.be","university":"Université libre de Bruxelles","programs":["Breast International Group","Breast cancer genomics and ctDNA","Early-phase trials","Haematology","Nuclear medicine"]},"route":"/institutions/institut-jules-bordet/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"company":[{"id":"big","kind":"company","name":"Breast International Group (BIG)","route":"/companies/big/"},{"id":"curie-nki-eortc","kind":"company","name":"EORTC","route":"/companies/curie-nki-eortc/"}],"institution":[{"id":"king-albert-ii-cancer-institute","kind":"institution","name":"King Albert II Cancer Institute, Cliniques universitaires Saint-Luc","route":"/institutions/king-albert-ii-cancer-institute/"},{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"}],"person":[{"id":"evandro-de-azambuja","kind":"person","name":"Evandro de Azambuja","route":"/people/evandro-de-azambuja/"},{"id":"martine-piccart","kind":"person","name":"Martine Piccart","route":"/people/martine-piccart/"},{"id":"renaud-witmeur","kind":"person","name":"Renaud Witmeur","route":"/people/renaud-witmeur/"},{"id":"sacha-gougnard","kind":"person","name":"Sacha Gougnard","route":"/people/sacha-gougnard/"}],"paper":[{"id":"paper-puleo-pancreatic-tumour-microenvironment-subtypes-gastroenterology-2018","kind":"paper","name":"Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features","route":"/key-papers/paper-puleo-pancreatic-tumour-microenvironment-subtypes-gastroenterology-2018/"},{"id":"paper-bareche-tnbc-microenvironment-jnci-2020","kind":"paper","name":"Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach","route":"/key-papers/paper-bareche-tnbc-microenvironment-jnci-2020/"},{"id":"paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018","kind":"paper","name":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","route":"/key-papers/paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018/"}]}}